Journal Article Epublish
PubMed: 40653502 DOI: 10.1038/s41541-025-01203-z
Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines.
NPJ Vaccines 10(1):153
Authors: Guy de Bruyn, Haritha Adhikarla, Caroline K Brackett, Yichen Jia, Premkumar Lakshmanane, Sarah V Mudrak, Sheetal Sawant, Donghui Zhang, Roman M Chicz, Saranya Sridhar, Georgia D Tomaras, Kelly E Seaton
Affiliations
- Sanofi Vaccines Research & Development, Swiftwater, PA, USA.
- Sanofi Vaccines Research & Development, Swiftwater, PA, USA.
- Department of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University, Durham, NC, USA.
- Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.
- Sanofi Vaccines R&D, Orlando, FL, USA.
- Sanofi Vaccines R&D, Waltham, MA, USA.
- Sanofi Vaccines R&D, Reading, UK.
Abstract
We included measurement of pre-existing immunity to human endemic coronaviruses (HCoV) in a Phase I/II study of SARS-CoV-2 spike protein vaccine candidates. A Binding Antibody Multiplex Assay measured HCoV-specific IgG to the receptor binding domain or full-length spike of human coronaviruses HKU1, 229E, NL63, and OC43. We found no evidence for the impact of HCoV antibodies on neutralizing and binding antibody responses to the candidate SARS-CoV-2 vaccines.
MeSH
Coronavirus, Sars-Cov-2, Vaccines, Severe Acute Respiratory Syndrome-Related Coronavirus